WO2003024942A1 - Derive thiazolidine et son utilisation medicamenteuse - Google Patents

Derive thiazolidine et son utilisation medicamenteuse Download PDF

Info

Publication number
WO2003024942A1
WO2003024942A1 PCT/JP2002/009419 JP0209419W WO03024942A1 WO 2003024942 A1 WO2003024942 A1 WO 2003024942A1 JP 0209419 W JP0209419 W JP 0209419W WO 03024942 A1 WO03024942 A1 WO 03024942A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolidine derivative
remedy
preventive
medicinal use
derivative
Prior art date
Application number
PCT/JP2002/009419
Other languages
English (en)
French (fr)
Inventor
Hiroshi Sakashita
Tomohiro Yoshida
Hiroshi Kitajima
Masahiro Takeuchi
Yoshihito Tanaka
Takuya Yoshimura
Fumihiko Akahoshi
Yoshiharu Hayashi
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Priority to US10/489,622 priority Critical patent/US20040259883A1/en
Priority to KR10-2004-7003689A priority patent/KR20040033048A/ko
Priority to EP02767958A priority patent/EP1426366A4/en
Priority to JP2003528790A priority patent/JPWO2003024942A1/ja
Priority to CA002460512A priority patent/CA2460512A1/en
Publication of WO2003024942A1 publication Critical patent/WO2003024942A1/ja
Priority to US11/774,941 priority patent/US7790725B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/JP2002/009419 2001-09-14 2002-09-13 Derive thiazolidine et son utilisation medicamenteuse WO2003024942A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/489,622 US20040259883A1 (en) 2001-09-14 2002-09-13 Thiazolidine derivative and medicinal use thereof
KR10-2004-7003689A KR20040033048A (ko) 2001-09-14 2002-09-13 티아졸리딘 유도체 및 이의 약학적 용도
EP02767958A EP1426366A4 (en) 2001-09-14 2002-09-13 THIAZOLIDE DERIVATIVES AND THEIR MEDICAL USE
JP2003528790A JPWO2003024942A1 (ja) 2001-09-14 2002-09-13 チアゾリジン誘導体およびその医薬用途
CA002460512A CA2460512A1 (en) 2001-09-14 2002-09-13 Thiazolidine derivatives and medicinal use thereof
US11/774,941 US7790725B2 (en) 2001-09-14 2007-07-09 Thiazolidine derivatives and medicinal use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001279084 2001-09-14
JP2001-279084 2001-09-14
JP2001304650 2001-09-28
JP2001-304650 2001-09-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10489622 A-371-Of-International 2002-09-13
US11/774,941 Division US7790725B2 (en) 2001-09-14 2007-07-09 Thiazolidine derivatives and medicinal use thereof

Publications (1)

Publication Number Publication Date
WO2003024942A1 true WO2003024942A1 (fr) 2003-03-27

Family

ID=26622197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009419 WO2003024942A1 (fr) 2001-09-14 2002-09-13 Derive thiazolidine et son utilisation medicamenteuse

Country Status (8)

Country Link
US (2) US20040259883A1 (ja)
EP (1) EP1426366A4 (ja)
JP (1) JPWO2003024942A1 (ja)
KR (1) KR20040033048A (ja)
CN (1) CN100341862C (ja)
CA (1) CA2460512A1 (ja)
TW (1) TWI246510B (ja)
WO (1) WO2003024942A1 (ja)

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016587A1 (ja) * 2002-08-19 2004-02-26 Ono Pharmaceutical Co., Ltd. 含窒素化合物
WO2004098625A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2006001750A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab Imidazole variants as modulators of gaba receptor for the treatment of gi disorders
US7026316B2 (en) 2001-03-27 2006-04-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
US7132443B2 (en) 2001-06-27 2006-11-07 Smithklinebeecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2006129785A1 (ja) * 2005-06-03 2006-12-07 Mitsubishi Tanabe Pharma Corporation 医薬の併用およびその用途
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
US7348346B2 (en) 2004-03-08 2008-03-25 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008120813A1 (ja) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
EP2165703A2 (en) 2004-01-20 2010-03-24 Novartis Pharma AG. Direct compression formulation and process
US7696250B2 (en) 2005-03-21 2010-04-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
EP2191824A1 (en) 2005-06-10 2010-06-02 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
EP2206496A1 (en) 2003-05-05 2010-07-14 Probiodrug AG Medical use of inhibitors of glutaminyl and glutamate cyclases
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2338490A2 (en) 2003-11-03 2011-06-29 Probiodrug AG Combinations Useful for the Treatment of Neuronal Disorders
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012165547A1 (ja) * 2011-06-01 2012-12-06 田辺三菱製薬株式会社 ピラゾール誘導体の製造方法
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2013154109A1 (ja) * 2012-04-10 2013-10-17 大日本住友製薬株式会社 新規１位置換インダゾール誘導体
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014061031A1 (en) 2012-10-17 2014-04-24 Cadila Healthcare Limited 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US8853385B2 (en) 2008-01-17 2014-10-07 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2839832A2 (en) 2003-11-17 2015-02-25 Novartis AG Use of dipeptidyl peptidase IV inhibitors
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
JP2015096495A (ja) * 2013-10-08 2015-05-21 大日本住友製薬株式会社 新規１位置換インダゾール誘導体からなる医薬
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
RU2006107553A (ru) 2003-08-13 2007-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
ATE437870T1 (de) 2004-05-12 2009-08-15 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006008644A1 (en) * 2004-07-13 2006-01-26 Pfizer Products Inc. Antidiabetic compounds
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
EP2602259A3 (en) 2005-02-18 2014-09-10 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
WO2006134613A2 (en) * 2005-06-17 2006-12-21 Aurigene Discovery Technologies Limited Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors
CA2632021A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
CN101341128A (zh) * 2005-12-23 2009-01-07 阿斯利康(瑞典)有限公司 用于治疗gerd和ibs的吡唑
BRPI0620373A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis dos mesmos, e enantiÈmeros do composto e sais dos mesmos, uso dos mesmos, opcionalmente em combinação com um agonista do receptor de gabab,e , composição farmaceutica
JP2009521426A (ja) * 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ ヘテロ環ｇａｂａ−ｂモジュレーター
WO2007073298A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
CL2007001011A1 (es) 2006-04-11 2008-05-16 Arena Pharm Inc Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
RU2009138135A (ru) * 2007-04-18 2011-05-27 Астразенека Аб (Se) Ксантиновые соединения, обладающие положительным аллостерическим модуляторным действием в отношении gabab
WO2008130313A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Imidazole derivatives as modulators of the gaba receptor for the treatment of gastrointestinal disorders
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102573478B (zh) 2009-10-12 2015-12-16 拜尔农作物科学股份公司 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TWI704145B (zh) 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
CN105085510B (zh) * 2015-09-11 2018-03-02 沧州那瑞化学科技有限公司 一种(s)‑4‑氧代‑2‑(噻唑烷‑3‑羰基)吡咯烷‑1‑羧酸叔丁酯的制备方法
WO2018034917A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
EP3496716B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
KR102068299B1 (ko) * 2018-12-21 2020-01-20 한국기초과학지원연구원 Cyp4a 저해 화합물을 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450352A1 (en) * 1990-03-30 1991-10-09 POLI INDUSTRIA CHIMICA S.p.A. Liposome formulations of immunomodulating drugs for the topical and aerosol administrations
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
US5462928A (en) * 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
DE19826972A1 (de) * 1998-06-18 1999-12-23 Univ Magdeburg Tech Verwendung von Enzyminhibitoren und pharmazeutische Zubereitung zur Therapie von dermatologischen Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation
WO2001081337A1 (en) * 2000-04-26 2001-11-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
WO2002014271A1 (fr) * 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Dérivés de proline et leur utilisation comme médicaments
WO2002068420A1 (de) * 2001-02-24 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
JP2002265439A (ja) * 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
EP1245568A1 (fr) * 2001-03-28 2002-10-02 Les Laboratoires Servier Dérives sulfonyles d'-aminoacides et leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV ( DPP IV)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450352A1 (en) * 1990-03-30 1991-10-09 POLI INDUSTRIA CHIMICA S.p.A. Liposome formulations of immunomodulating drugs for the topical and aerosol administrations
US5462928A (en) * 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
DE19826972A1 (de) * 1998-06-18 1999-12-23 Univ Magdeburg Tech Verwendung von Enzyminhibitoren und pharmazeutische Zubereitung zur Therapie von dermatologischen Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation
WO2001081337A1 (en) * 2000-04-26 2001-11-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
WO2002014271A1 (fr) * 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Dérivés de proline et leur utilisation comme médicaments
WO2002068420A1 (de) * 2001-02-24 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
JP2002265439A (ja) * 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
EP1245568A1 (fr) * 2001-03-28 2002-10-02 Les Laboratoires Servier Dérives sulfonyles d'-aminoacides et leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV ( DPP IV)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1426366A4 *

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026316B2 (en) 2001-03-27 2006-04-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7132443B2 (en) 2001-06-27 2006-11-07 Smithklinebeecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2004016587A1 (ja) * 2002-08-19 2004-02-26 Ono Pharmaceutical Co., Ltd. 含窒素化合物
WO2004098625A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP2206496A1 (en) 2003-05-05 2010-07-14 Probiodrug AG Medical use of inhibitors of glutaminyl and glutamate cyclases
DE202004021723U1 (de) 2003-05-05 2010-07-15 Probiodrug Ag Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
EP2338490A2 (en) 2003-11-03 2011-06-29 Probiodrug AG Combinations Useful for the Treatment of Neuronal Disorders
EP2839832A2 (en) 2003-11-17 2015-02-25 Novartis AG Use of dipeptidyl peptidase IV inhibitors
EP3738585A1 (en) 2004-01-20 2020-11-18 Novartis Ag Direct compression formulation and process
EP3366283A1 (en) 2004-01-20 2018-08-29 Novartis AG Direct compression formulation and process
EP3023095A1 (en) 2004-01-20 2016-05-25 Novartis AG Direct compression formulation and process
EP2165703A2 (en) 2004-01-20 2010-03-24 Novartis Pharma AG. Direct compression formulation and process
US7897633B2 (en) 2004-02-05 2011-03-01 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US7671076B2 (en) 2004-03-08 2010-03-02 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7348346B2 (en) 2004-03-08 2008-03-25 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2006001750A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab Imidazole variants as modulators of gaba receptor for the treatment of gi disorders
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US7696250B2 (en) 2005-03-21 2010-04-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
US8013183B2 (en) 2005-03-21 2011-09-06 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
US8450373B2 (en) 2005-03-21 2013-05-28 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
WO2006129785A1 (ja) * 2005-06-03 2006-12-07 Mitsubishi Tanabe Pharma Corporation 医薬の併用およびその用途
US8754032B2 (en) 2005-06-03 2014-06-17 Mitsubishi Tanabe Pharma Corporation Concomitant pharmaceutical agents and use thereof
EP2191824A1 (en) 2005-06-10 2010-06-02 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008120813A1 (ja) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8853385B2 (en) 2008-01-17 2014-10-07 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JPWO2012165547A1 (ja) * 2011-06-01 2015-02-23 田辺三菱製薬株式会社 ピラゾール誘導体の製造方法
WO2012165547A1 (ja) * 2011-06-01 2012-12-06 田辺三菱製薬株式会社 ピラゾール誘導体の製造方法
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US8765786B2 (en) 2012-04-10 2014-07-01 Dainippon Sumitomo Pharma Co., Ltd. 1-substituted indazole derivative
CN104395292A (zh) * 2012-04-10 2015-03-04 大日本住友制药株式会社 新的1-取代的吲唑衍生物
US9309221B2 (en) 2012-04-10 2016-04-12 Sumitomo Dainippon Pharma Co., Ltd. 1-substituted indazole derivative
US9051295B2 (en) 2012-04-10 2015-06-09 Sumitomo Dainippon Pharma Co., Ltd. 1-substituted indazole derivative
WO2013154109A1 (ja) * 2012-04-10 2013-10-17 大日本住友製薬株式会社 新規１位置換インダゾール誘導体
JPWO2013154109A1 (ja) * 2012-04-10 2015-12-17 大日本住友製薬株式会社 新規１位置換インダゾール誘導体
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014061031A1 (en) 2012-10-17 2014-04-24 Cadila Healthcare Limited 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2015096495A (ja) * 2013-10-08 2015-05-21 大日本住友製薬株式会社 新規１位置換インダゾール誘導体からなる医薬
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
TWI246510B (en) 2006-01-01
EP1426366A1 (en) 2004-06-09
US20070259880A1 (en) 2007-11-08
CN100341862C (zh) 2007-10-10
US7790725B2 (en) 2010-09-07
EP1426366A4 (en) 2004-12-08
CN1606549A (zh) 2005-04-13
JPWO2003024942A1 (ja) 2004-12-24
US20040259883A1 (en) 2004-12-23
KR20040033048A (ko) 2004-04-17
CA2460512A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2003024942A1 (fr) Derive thiazolidine et son utilisation medicamenteuse
AU6520998A (en) 1,4-substituted cyclic amine derivatives
HK1077567A1 (en) Dibenzylamine compound and medicinal use thereof
CA2267103A1 (en) Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
EP1386920A4 (en) DERIVATIVES OF BENZIMIDAZOLONE
EP1669352A4 (en) THIAZOLINE DERIVATIVE AND ITS USE
EP1724258A4 (en) HETEROARYLPHENYLUREE DERIVATIVE
EP1734040A4 (en) SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
HK1048989A1 (en) Heterocyclic derivatives and pharmaceutical use thereof.
EP1008592A3 (en) Cyclic amide derivatives which inhibit cathepsin K
CA2126465A1 (en) Inhibitor for restenosis after percutaneous coronary arterioplasty
EP1176141A4 (en) HETEROCYCLIC COMPOUNDS HAVING RECEPTOR ACTIVATION EFFECT $ g (a) 4 $ g (b) 2 OF NICOTINIC ACETYLCHOLINE
WO2000068198A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
WO2008114812A1 (ja) Jak阻害剤
EP1535922A4 (en) PYRROLOPYRIDINE DERIVATIVE AND ITS USE
EP1364950A4 (en) PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
WO2000064874A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
WO2003059907A1 (fr) Composes heterocycliques azotes : procede de preparation et d'utilisation
EP1550651A4 (en) GLYCEROL DERIVATIVE
EP1537879A4 (en) PREVENTIVE AND / OR THERAPEUTIC DRUGS AGAINST ASTHMA
AU6731100A (en) Integrase inhibitors containing aromatic heterocycle derivatives
WO2009054401A1 (ja) 複素芳香族化合物を有効成分とする抗ウイルス剤
AU6594900A (en) Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof andagents
DK1340756T3 (da) Hidtil ukendte beta-lactamforbindelser og fremgangsmåde til fremstilling deraf
EP1637530A4 (en) THERAPEUTIC AGENT FOR SENILE DEMENTIA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003528790

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2460512

Country of ref document: CA

Ref document number: 1020047003689

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028180844

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002767958

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10489622

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002767958

Country of ref document: EP